Greater white and grey matter changes associated with early cannabis use in adolescent-onset schizophrenia (AOS)

Schizophrenia Research

Volumn 128, Issue 1-3, 2011, Pages 91-97

  James, A ^a,b   Hough, M ^b   James, S ^a   Winmill, L ^a   Burge, L ^a   Nijhawan, S ^a   Matthews, P M ^b,c   Zarei, M ^b,c  

^a WARNEFORD HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Adolescence; Brain structure; Cannabis; DTI; Schizophrenia

Indexed keywords

CHLORPROMAZINE;

ADOLESCENT; AGE DISTRIBUTION; ARCUATE FASCICULUS; ARTICLE; BRAIN SIZE; BRAIN STEM; CANNABIS SMOKING; CAPSULA INTERNA; CEREBELLUM; CINGULATE GYRUS; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORONA RADIATA (BRAIN); CORPUS CALLOSUM; CORPUS STRIATUM; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIFFUSION TENSOR IMAGING; DISEASE DURATION; FAMILY HISTORY; FEMALE; FRACTIONAL ANISOTROPY; FUSIFORM GYRUS; GRAY MATTER; HUMAN; INSULA; INTELLIGENCE; INTELLIGENCE QUOTIENT; MALE; MIDDLE TEMPORAL GYRUS; MOTOR CORTEX; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; ONSET AGE; PARAHIPPOCAMPAL GYRUS; POSITIVE AND NEGATIVE SYNDROME SCALE; POSTCENTRAL GYRUS; PRECUNEUS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; VOXEL BASED MORPHOMETRY; WHITE MATTER;

ADOLESCENT; ANISOTROPY; BRAIN; BRAIN MAPPING; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MARIJUANA ABUSE; MULTIVARIATE ANALYSIS; NERVE FIBERS, MYELINATED; SCHIZOPHRENIA;

EID: 79955473476     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2011.02.014     Document Type: Article

References (80)

1. Andreasen N.C., Endicott J., Spitzer R.L., Winokur G. The family history method using diagnostic criteria. Reliability and validity. Arch. Gen. Psychiatry 1977, 34:1229-1235.
2. Andreasen N.C., Nopoulos P., O'Leary D.S., Miller D.D., Wassink T., Flaum M. Defining the phenotype of schizophrenia: cognitive dysmetria and its neural mechanisms. Biol. Psychiatry 1999, 46:908-920.
3. Andreasson S., Allebeck P., Engstrom A., Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987, 2:1483-1486.
4. American Psychiatric Association - APA (1994). Diagnostic and Statistical Manual of Mental Disorders. Washington, DC.
5. Arevalo-Martin A., Garcia-Ovejero D., Rubio-Araiz A., Gomez O., Molina-Holgado F., Molina-Holgado E. Cannabinoids modulate Olig2 and polysialylated neural cell adhesion molecule expression in the subventricular zone of post-natal rats through cannabinoid receptor 1 and cannabinoid receptor 2. Eur. J. Neurosci. 2007, 26:1548-1559.
6. Arnone D., Barrick T.R., Chengappa S., Mackay C.E., Clark C.A., Abou-Saleh M.T. Corpus callosum damage in heavy marijuana use: preliminary evidence from diffusion tensor tractography and tract-based spatial statistics. Neuroimage 2008, 41:1067-1074.
7. Arseneault L., Cannon M., Poulton R., Murray R., Caspi A., Moffitt T.E. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002, 325:1212-1213.
8. Basavarajappa B.S., Nixon R.A., Arancio O. Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration. Mini Rev. Med. Chem. 2009, 9:448-462.
9. Bhattacharyya S., Fusar-Poli P., Borgwardt S., Martin-Santos R., Nosarti C., O'Carroll C., Allen P., Seal M.L., Fletcher P.C., Crippa J.A., Giampietro V., Mechelli A., Atakan Z., McGuire P. Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch. Gen. Psychiatry 2009, 66:442-451.
10. Bossong M.G., Niesink R.J. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Prog. Neurobiol. 2010, 92:370-385.
11. Bossong M.G., van Berckel B.N., Boellaard R., Zuurman L., Schuit R.C., Windhorst A.D., van Gerven J.M., Ramsey N.F., Lammertsma A.A., Kahn R.S. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009, 34:759-766.
12. Coulston C.M., Perdices M., Tennant C.C. The neuropsychological correlates of cannabis use in schizophrenia: lifetime abuse/dependence, frequency of use, and recency of use. Schizophr. Res. 2007, 96:169-184.
13. Dekker N., Schmitz N., Peters B.D., van Amelsvoort T.A., Linszen D.H., de Haan L. Cannabis use and callosal white matter structure and integrity in recent-onset schizophrenia. Psychiatry Res. 2011, 181:51-56.
14. DeLisi L.E. The effect of cannabis on the brain: can it cause brain anomalies that lead to increased risk for schizophrenia?. Curr. Opin. Psychiatry 2008, 21:140-150.
15. Douaud G., Smith S., Jenkinson M., Behrens T., Johansen-Berg H., Vickers J., James S., Voets N., Watkins K., Matthews P.M., James A. Anatomically related grey and white matter abnormalities in adolescent-onset schizophrenia. Brain 2007, 130:2375-2386.
16. Douaud G., Mackay C., Andersson J., James S., Quested D., Ray M.K., Connell J., Roberts N., Crow T.J., Matthews P.M., Smith S., James A. Schizophrenia delays and alters maturation of the brain in adolescence. Brain 2009, 132:2437-2448.
17. Fergusson D.M., Horwood L.J., Swain-Campbell N.R. Cannabis dependence and psychotic symptoms in young people. Psychol. Med. 2003, 33:15-21.
18. Fernandez-Espejo E., Viveros M.P., Nunez L., Ellenbroek B.A., Rodriguez de Fonseca F. Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology (Berl.) 2009, 206:531-549.
19. Fride E. Multiple roles for the endocannabinoid system during the earliest stages of life: pre- and postnatal development. J. Neuroendocrinol. 2008, 20(Suppl. 1):75-81.
20. Genovese C.R., Lazar N.A., Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 2002, 15:870-878.
21. Giedd J.N. The teen brain: insights from neuroimaging. J. Adolesc. Health 2008, 42:335-343.
22. Gogtay N. Cortical brain development in schizophrenia: insights from neuroimaging studies in childhood-onset schizophrenia. Schizophr. Bull. 2008, 34:30-36.
23. Gomez M., Hernandez M., Fernandez-Ruiz J. The activation of cannabinoid receptors during early postnatal development reduces the expression of cell adhesion molecule L1 in the rat brain. Brain Res. 2007, 1145:48-55.
24. Goncalves M.B., Suetterlin P., Yip P., Molina-Holgado F., Walker D.J., Oudin M.J., Zentar M.P., Pollard S., Yanez-Munoz R.J., Williams G., Walsh F.S., Pangalos M.N., Doherty P. A diacylglycerol lipase-CB2 cannabinoid pathway regulates adult subventricular zone neurogenesis in an age-dependent manner. Mol. Cell. Neurosci. 2008, 38:526-536.
25. Good C.D., Johnsrude I.S., Ashburner J., Henson R.N., Friston K.J., Frackowiak R.S. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 2001, 14:21-36.
26. Grant I., Gonzalez R., Carey C.L., Natarajan L., Wolfson T. Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J. Int. Neuropsychol. Soc. 2003, 9:679-689.
27. Gruber S.A., Yurgelun-Todd D.A. Neuroimaging of marijuana smokers during inhibitory processing: a pilot investigation. Brain Res. Cogn. Brain Res. 2005, 23:107-118.
28. Henquet C., Krabbendam L., Spauwen J., Kaplan C., Lieb R., Wittchen H.U., van Os J. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005, 330:11.
29. Henquet C., Murray R., Linszen D., van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr. Bull. 2005, 31:608-612.
30. Hollis C., Groom M.J., Das D., Calton T., Bates A.T., Andrews H.K., Jackson G.M., Liddle P.F. Different psychological effects of cannabis use in adolescents at genetic high risk for schizophrenia and with attention deficit/hyperactivity disorder (ADHD). Schizophr. Res. 2008, 105:216-223.
31. Jacobus J., McQueeny T., Bava S., Schweinsburg B.C., Frank L.R., Yang T.T., Tapert S.F. White matter integrity in adolescents with histories of marijuana use and binge drinking. Neurotoxicol. Teratol. 2009, 31:349-355.
32. Jager G., Van Hell H.H., De Win M.M., Kahn R.S., Van Den Brink W., Van Ree J.M., Ramsey N.F. Effects of frequent cannabis use on hippocampal activity during an associative memory task. Eur. Neuropsychopharmacol. 2007, 17:289-297.
33. James A.C., James S., Smith D.M., Javaloyes A. Cerebellar, prefrontal cortex, and thalamic volumes over two time points in adolescent-onset schizophrenia. Am. J. Psychiatry 2004, 161:1023-1029.
34. Jockers-Scherubl M.C., Wolf T., Radzei N., Schlattmann P., Rentzsch J., Gomez-Carrillo de Castro A., Kuhl K.P. Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1054-1063.
35. Kaufman J., Birmaher B., Brent D., Rao U., Flynn C., Moreci P., Williamson D., Ryan N. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J. Am. Acad. Child Adolesc. Psychiatry 1997, 36:980-988.
36. Kay S.R., Opler L.A., Lindenmayer J.P. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br. J. Psychiatry Suppl. 1989, 59-67.
37. Konings M., Henquet C., Maharajh H.D., Hutchinson G., Van Os J. Early exposure to cannabis and risk for psychosis in young adolescents in Trinidad. Acta Psychiatr. Scand. 2008, 118:209-213.
38. Kuepper R., Morrison P.D., van Os J., Murray R.M., Kenis G., Henquet C. Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. Schizophr. Res. 2010, 121:107-117.
39. Kumra S., Thaden E., DeThomas C., Kranzler H. Correlates of substance abuse in adolescents with treatment-refractory schizophrenia and schizoaffective disorder. Schizophr. Res. 2005, 73:369-371.
40. Leweke F.M., Giuffrida A., Wurster U., Emrich H.M., Piomelli D. Elevated endogenous cannabinoids in schizophrenia. NeuroReport 1999, 10:1665-1669.
41. Macleod J. Cannabis use and symptom experience amongst people with mental illness: a commentary on Degenhardt et al. Psychol. Med. 2007, 37:913-916.
42. Malone D.T., Hill M.N., Rubino T. Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Br. J. Pharmacol. 2010, 160:511-522.
43. Matochik J.A., Eldreth D.A., Cadet J.L., Bolla K.I. Altered brain tissue composition in heavy marijuana users. Drug Alcohol Depend. 2005, 77:23-30.
44. Mauri M.C., Volonteri L.S., De Gaspari I.F., Colasanti A., Brambilla M.A., Cerruti L. Substance abuse in first-episode schizophrenic patients: a retrospective study. Clin. Pract. Epidemiol. Ment. Health 2006, 2:4.
45. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-328.
46. Murray R.M., Lappin J., Di Forti M. Schizophrenia: from developmental deviance to dopamine dysregulation. Eur. Neuropsychopharmacol. 2008, 18(Suppl. 3):S129-S134.
47. Nichols T.E., Holmes A.P. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum. Brain Mapp. 2002, 15:1-25.
48. Oldfield R.C. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 1971, 9:97-113.
49. Patenaude, B., 2007, Bayesian Statistical Models of Shape and Appearance for Subcortical Brain Segmentation, Department of Neurology D.Phil. Thesis. University of Oxford.
50. Peters B.D., de Haan L., Vlieger E.J., Majoie C.B., den Heeten G.J., Linszen D.H. Recent-onset schizophrenia and adolescent cannabis use: MRI evidence for structural hyperconnectivity?. Psychopharmacol. Bull. 2009, 42:75-88.
51. Peters B.D., Blaas J., de Haan L. Diffusion tensor imaging in the early phase of schizophrenia: what have we learned?. J. Psychiatr. Res. 2010, 44:993-1004.
52. Pistis M., Perra S., Pillolla G., Melis M., Muntoni A.L., Gessa G.L. Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. Biol. Psychiatry 2004, 56:86-94.
53. Pope H.G., Gruber A.J., Hudson J.I., Cohane G., Huestis M.A., Yurgelun-Todd D. Early-onset cannabis use and cognitive deficits: what is the nature of the association?. Drug Alcohol Depend. 2003, 69:303-310.
54. Rais M., Cahn W., Van Haren N., Schnack H., Caspers E., Hulshoff Pol H., Kahn R. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am. J. Psychiatry 2008, 165:490-496.
55. Rodriguez de Fonseca F., Ramos J.A., Bonnin A., Fernandez-Ruiz J.J. Presence of cannabinoid binding sites in the brain from early postnatal ages. NeuroReport 1993, 4:135-138.
56. Rodriguez-Sanchez J.M., Ayesa-Arriola R., Mata I., Moreno-Calle T., Perez-Iglesias R., Gonzalez-Blanch C., Perianez J.A., Vazquez-Barquero J.L., Crespo-Facorro B. Cannabis use and cognitive functioning in first-episode schizophrenia patients. Schizophr. Res. 2010.
57. Schneider M. Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict. Biol. 2008, 13:253-263.
58. Semple D.M., McIntosh A.M., Lawrie S.M. Cannabis as a risk factor for psychosis: systematic review. J. Psychopharmacol. 2005, 19:187-194.
59. Smith S.M., Nichols T.E. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage 2009, 44:83-98.
60. Smith S.M., Jenkinson M., Woolrich M.W., Beckmann C.F., Behrens T.E., Johansen-Berg H., Bannister P.R., De Luca M., Drobnjak I., Flitney D.E., Niazy R.K., Saunders J., Vickers J., Zhang Y., De Stefano N., Brady J.M., Matthews P.M. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004, 23(Suppl. 1):S208-S219.
61. Smith S.M., Jenkinson M., Johansen-Berg H., Rueckert D., Nichols T.E., Mackay C.E., Watkins K.E., Ciccarelli O., Cader M.Z., Matthews P.M., Behrens T.E. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 2006, 31:1487-1505.
62. Sporn A.L., Greenstein D.K., Gogtay N., Jeffries N.O., Lenane M., Gochman P., Clasen L.S., Blumenthal J., Giedd J.N., Rapoport J.L. Progressive brain volume loss during adolescence in childhood-onset schizophrenia. Am. J. Psychiatry 2003, 160:2181-2189.
63. Stefanis N.C., Delespaul P., Henquet C., Bakoula C., Stefanis C.N., Van Os J. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction 2004, 99:1333-1341.
64. Szeszko P.R., Robinson D.G., Sevy S., Kumra S., Rupp C.I., Betensky J.D., Lencz T., Ashtari M., Kane J.M., Malhotra A.K., Gunduz-Bruce H., Napolitano B., Bilder R.M. Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. Br. J. Psychiatry 2007, 190:230-236.
65. Tamnes C.K., Ostby Y., Walhovd K.B., Westlye L.T., Due-Tonnessen P., Fjell A.M. Intellectual abilities and white matter microstructure in development: A diffusion tensor imaging study. Hum. Brain Mapp. 2010.
66. Thompson P.M., Sowell E.R., Gogtay N., Giedd J.N., Vidal C.N., Hayashi K.M., Leow A., Nicolson R., Rapoport J.L., Toga A.W. Structural MRI and brain development. Int. Rev. Neurobiol. 2005, 67:285-323.
67. Tzavara E.T., Li D.L., Moutsimilli L., Bisogno T., Di Marzo V., Phebus L.A., Nomikos G.G., Giros B. Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biol. Psychiatry 2006, 59:508-515.
68. Tzilos G.K., Cintron C.B., Wood J.B., Simpson N.S., Young A.D., Pope H.G., Yurgelun-Todd D.A. Lack of hippocampal volume change in long-term heavy cannabis users. Am. J. Addict. 2005, 14:64-72.
69. van Os J., Bak M., Hanssen M., Bijl R.V., de Graaf R., Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am. J. Epidemiol. 2002, 156:319-327.
70. van Os J., Rutten B.P., Poulton R. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr. Bull. 2008, 34:1066-1082.
71. Veen N.D., Selten J.P., van der Tweel I., Feller W.G., Hoek H.W., Kahn R.S. Cannabis use and age at onset of schizophrenia. Am. J. Psychiatry 2004, 161:501-506.
72. Veling W., Mackenbach J.P., van Os J., Hoek H.W. Cannabis use and genetic predisposition for schizophrenia: a case-control study. Psychol. Med. 2008, 38:1251-1256.
73. Wechsler D. Wechsler Abbreviated Scale of Intelligence 1999, The Psychological Corporation, San Antonio.
74. Wenger T., Gerendai I., Fezza F., Gonzalez S., Bisogno T., Fernandez-Ruiz J., Di Marzo V. The hypothalamic levels of the endocannabinoid, anandamide, peak immediately before the onset of puberty in female rats. Life Sci. 2002, 70:1407-1414.
75. Whalley H.C., Simonotto E., Flett S., Marshall I., Ebmeier K.P., Owens D.G., Goddard N.H., Johnstone E.C., Lawrie S.M. fMRI correlates of state and trait effects in subjects at genetically enhanced risk of schizophrenia. Brain 2004, 127:478-490.
76. White T., Ho B.C., Ward J., O'Leary D., Andreasen N.C. Neuropsychological performance in first-episode adolescents with schizophrenia: a comparison with first-episode adults and adolescent control subjects. Biol. Psychiatry 2006, 60:463-471.
77. Yucel M., Solowij N., Respondek C., Whittle S., Fornito A., Pantelis C., Lubman D.I. Regional brain abnormalities associated with long-term heavy cannabis use. Arch. Gen. Psychiatry 2008, 65:694-701.
78. Yucel M., Bora E., Lubman D.I., Solowij N., Brewer W.J., Cotton S.M., Conus P., Takagi M.J., Fornito A., Wood S.J., McGorry P.D., Pantelis C. The Impact of Cannabis Use on Cognitive Functioning in Patients With Schizophrenia: A Meta-analysis of Existing Findings and New Data in a First-Episode Sample. Schizophr Bull. 2010.
79. Yucel M., Zalesky A., Takagi M.J., Bora E., Fornito A., Ditchfield M., Egan G.F., Pantelis C., Lubman D.I. White-matter abnormalities in adolescents with long-term inhalant and cannabis use: a diffusion magnetic resonance imaging study. J. Psychiatry Neurosci. 2010, 35:409-412.
80. Zammit S., Allebeck P., David A.S., Dalman C., Hemmingsson T., Lundberg I., Lewis G. A longitudinal study of premorbid IQ Score and risk of developing schizophrenia, bipolar disorder, severe depression, and other nonaffective psychoses. Arch. Gen. Psychiatry 2004, 61:354-360.